Scheduled for June 23 rd the CD19 Vaccine for cancer.A small company located in Texas will release it’s findings and results
from 110 clinical trials on a treatment centered on a patients immune
system where the T cell will recognize and phagotize the cancer cell.
The release of their findings should lead to licensing fees that should
cause the price of the stock to explode.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Hello, I have been trying to determine what the likely candidate is, but we seem to be all over the map on this one. Is it BLCM, or ZIOP, or PHMMF or PHM.MC, or BPTH, and finally OPBG. Are all these entities presenting at the 22nd Congress, or is it only BLCM?
Bellicum Pharmaceuticals Inc BLCM.
I would like to know it if anybody have answer and kind to share with us! Thank you,
John Weinberg
Bellicum Pharmaceuticals Inc.,Houston,United States
Speaker of
(S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 15:45 – 15:57
(P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 17:15 – 18:45
(S495) IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT
Pietro Merli (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Saturday 17:00 – 17:15
Author of
(S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 15:45 – 15:57
(P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 17:15 – 18:45
Annemarie Moseley
Bellicum Pharmaceuticals Inc.,Houston,United States
Speaker of
(S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 15:45 – 15:57
(P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 17:15 – 18:45
(S495) IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT
Pietro Merli (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Saturday 17:00 – 17:15
Its absolutely correct the abstracts are released – they were posted to the EHA website on 18th May. I read the abstract – it is one of the “Top 6” abstracts to be presented in the “presidential” session. . Even to a layman it is very impressive (they data relates to stem cell transplants)
1) About 70 non-malignants – 100% survival in stell cell transplant even if not a perfect match – not sure what the mortality would be normally but 100% clearly cant be beaten
2) About 40 malignants – approx 97 % survival 1 year later, spread across 4-5 conditions
So, the reason they are presenting is nothing to do with “cancer vaccine” – they are trying to prove that their process makes transplants safer – cant argue with that. And I can see why they have gone under the radar – their number 1 goal is to make transplant safe – and “by the way” they have done transplants on people with cancer most of who have survived 1 year which is 10x greater than normal. That is the key point in relationt to the teaser, but is it not the main goal of the trial. I dont think releasing this on the 23rd will necessarily move the price much – but I do think it will light a blue touch paper once the incredible survival data becomes clear – im not sure if the regulators will ask them to un-bundle the 40 or so malignants into several trials (as the 40 have various conditions) however the treament seems to stop all of them in its tracks – clearly cant extrapolate that to solid tumours (they have a follow up product for pancreatic cancer) but the potential is there without question – I dont see how this company can stay with a value of $400m for long. But it may take time
There are 7 presenters from OPG. All are talking about the same thing in association with Bellicum’s S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE)
I will show just 1 of the presenters schedule followed by the list of opg speakers:
Franco Locatelli
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Speaker of
(S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 15:45 – 15:57
(P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Friday 17:15 – 18:45
(S495) IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT
Pietro Merli (Ospedale Pediatrico Bambino Gesu,Rome,Italy)
Saturday 17:00 – 17:15
Alice Bertaina
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Pietro Merli
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Federica Galaverna
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Daria Pagliara
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Franco Locatelli
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Mattia Algeri
Ospedale Pediatrico Bambino Gesu,Rome,Italy
Giuseppina Li Pira
Ospedale Pediatrico Bambino Gesu,Rome,Italy
I got an answer from Moleculin. You need to go through a broker or open an online investing account. No direct there. Still haven’t heard from Bellicum.
In Bellicum’s profile it shows this:
It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies
I went to the adaptimmune website and found a video quite similar to the one that is in the teaser adds.
This is the link if you would like to check i tout: (copy & paste)
http://www.adaptimmune.com/pipeline/pipeline-overview
STEVEX, THANK YOU SO MUCH for your VERY DILIGENT WORK on ALL of this!! You and Clive are to be COMMENDED for the REAL research being done here on behalf of this group!! I agree that, PERHAPS, NOT a lot will happen tomorrow; then, again, maybe it will. In ANY case, GOOD LUCK TO ALL regarding a future purchase of Bellicum!! From a stock or, stock option perspective, Bellicum is STILL HIGHLY UNDERVALUED at this point in time.
i agree with all who have complimented these professional men who have endeavoured to caution us all and yet not discourage us by using intelligence
and common sense to create a calm and safe enviorment to discuss this really very important annoucement.so i am very grateful and sincere when i say i will turn my 1500 clients to this site and will continue to participate in their discusions.
farm phone 7054354
Baker Brothers Advisors LP hold over 5 million shares of BLCM, as of 3/31/2017, and Julian Baker is also involved in some manner with Alexion Pharmaceuticals’ buying which has been very active with sizeable buys June 14-15.
Interesting enough… BLCM has gone up over a $1.40 as I write this and is currently trading at around $14.05 share.
BLCM in after hours = $14.77. Friday should be fun. 2 presentations >3:45-4 and 5:15-6:45. Don’t know if 4:00 to 5:15 is a dinner break or other presentations??? These are Madrid times. Good luck everyone!!!
what’s happening now? is it going to go back up from this pull back..you would think that a new discovery like this one would make it soar with little pull back..
My 8/18 15 dollar call options that I bought at the end of last week are up by 800%. I bought 15 of them for an average price of .37 cents. I just sold 5 yesterday at 1.50 (approx 400% gain) and got my initial money back and then some. Now I ride the other 10 contracts and see what happens. They closed st $2.45 today and the stock is up about another .65-.70 cents in after hours so the options will be up nicely in the morning from there and now hopefully good news and off the moon it goes. Fingers crossed.
The BLCM company is across the highway from the University and close to the hospital where they do the testing if this helps
what is the name of the company
Are you sure they don’t mean MBRX
Madrid Spain is + 7 hours in CD time zone. So that means 3:45 = 8:45 am Texas time
just interested…… Has anyone actually spent their money to gt the name direct from the “professionals”?
I don’t think so, because they offer the “professional” advise for $1997,- to $2497,- price!!! I learn more of this page, than any paid adviser.
My research shows Bellicum revenue for 2016…… £388,000.Therefore without paying the big bucks,this is too coincidental to ignore.
Presentation info released on BLCM web site – “news release”
who is the Co for cd19
anybody knows the company name
As everybody talking, it looks like BLCM, but I have also bought some of JUNO and MBRX. JUNO is now in phase 2 clinical stage of CD19.